Published in J Virol on September 01, 2001
The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe (2011) 2.25
Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther (2005) 2.21
Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A (2006) 1.71
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng (2008) 1.28
Viral vectors: from virology to transgene expression. Br J Pharmacol (2009) 1.19
In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J Virol (2002) 1.16
Role of phosphatidylserine receptors in enveloped virus infection. J Virol (2014) 1.10
Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells. J Virol (2005) 1.09
Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. J Virol (2005) 1.04
Mechanisms for Env glycoprotein acquisition by retroviruses. AIDS Res Hum Retroviruses (2011) 1.01
A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med (2009) 1.00
Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther (2010) 0.98
Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J Virol (2010) 0.97
Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol Ther (2011) 0.94
Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J Virol (2006) 0.91
Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization. J Acquir Immune Defic Syndr (2009) 0.91
Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol (2003) 0.91
Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J Gene Med (2009) 0.89
Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells. J Gene Med (2009) 0.89
Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors. J Biol Eng (2009) 0.87
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus. Antimicrob Agents Chemother (2011) 0.85
In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. Mol Cancer (2012) 0.85
Gamma-retroviral vectors enveloped with an antibody and an engineered fusogenic protein achieved antigen-specific targeting. Biotechnol Bioeng (2008) 0.84
Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol (2009) 0.84
Targeting lentiviral vector to specific cell types through surface displayed single chain antibody and fusogenic molecule. Virol J (2010) 0.84
Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13. Hum Gene Ther Methods (2012) 0.83
Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors. Acta Naturae (2013) 0.83
Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway. J Virol (2009) 0.83
Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus. Retrovirology (2010) 0.82
Lentiviral vectors for immune cells targeting. Immunopharmacol Immunotoxicol (2010) 0.81
Receptors and tropisms of envelope viruses. Curr Opin Virol (2011) 0.80
Retroviral env glycoprotein trafficking and incorporation into virions. Mol Biol Int (2012) 0.80
Library screening and receptor-directed targeting of gammaretroviral vectors. Future Microbiol (2013) 0.79
Antibody-mediated targeted gene transfer of helper virus-free HSV-1 vectors to rat neocortical neurons that contain either NMDA receptor 2B or 2A subunits. Brain Res (2011) 0.79
The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol J (2006) 0.79
Preferential lentiviral targeting of astrocytes in the central nervous system. PLoS One (2013) 0.78
Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm Res (2009) 0.78
Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells. J Biol Eng (2011) 0.78
A dual-targeted lentiviral vector homing in on prostate bone metastases. Mol Ther (2007) 0.77
Functional pseudotyping of human immunodeficiency virus type 1 vectors by Western equine encephalitis virus envelope glycoprotein. J Virol (2008) 0.76
Pseudotyping lentiviral vectors with aura virus envelope glycoproteins for DC-SIGN-mediated transduction of dendritic cells. Hum Gene Ther (2011) 0.76
Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med (2014) 0.76
Retargeting vesicular stomatitis virus glycoprotein pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell. Hum Gene Ther Methods (2013) 0.75
Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design. Mol Med (2007) 0.75
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol (1994) 5.17
Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science (1994) 3.97
A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site. Cell (1990) 2.63
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22
Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol (1994) 1.83
Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci U S A (1995) 1.80
Low-pH-dependent fusion of Sindbis virus with receptor-free cholesterol- and sphingolipid-containing liposomes. J Virol (1999) 1.69
A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci U S A (1989) 1.64
An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol (1999) 1.61
Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci U S A (1999) 1.48
A gene fusion system for generating antibodies against short peptides. Gene (1987) 1.42
Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol (1997) 1.39
Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci U S A (1995) 1.32
Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol (1996) 1.30
Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci U S A (1999) 1.25
Targeting of retroviral vectors through protease-substrate interactions. Gene Ther (1996) 1.15
Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J Virol (1998) 1.05
Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther (1996) 1.03
Retrovirus targeting by tropism restriction to melanoma cells. J Virol (1999) 0.97
Cell-specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant Sindbis virus vector. Int J Cancer (1999) 0.87
In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies. Gene Ther (1999) 0.86
Cell-specific transfection of choriocarcinoma cells by using Sindbis virus hCG expressing chimeric vector. Biochem Biophys Res Commun (1998) 0.83
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science (1987) 12.77
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42
Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene. Proc Natl Acad Sci U S A (1985) 4.28
Clearance of HIV infection in a perinatally infected infant. N Engl J Med (1995) 3.76
The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43
Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science (1984) 3.39
High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature (1990) 3.28
Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol (1991) 3.28
Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science (1988) 3.22
Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs. Genes Dev (1991) 3.06
High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science (1989) 3.00
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol (1997) 2.82
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method. J Virol (1989) 2.67
Nucleotide sequence analysis of the long terminal repeat of human T-cell leukemia virus type II. Proc Natl Acad Sci U S A (1984) 2.67
Characterization of reticuloendotheliosis virus strain T DNA and isolation of a novel variant of reticuloendotheliosis virus strain T by molecular cloning. J Virol (1981) 2.49
Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation. Nature (1986) 2.49
The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol (1992) 2.49
Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45
The x gene is essential for HTLV replication. Science (1985) 2.44
Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol (1989) 2.42
Human T-cell leukemia virus type II transforms normal human lymphocytes. Proc Natl Acad Sci U S A (1983) 2.41
Long terminal repeats of human T-cell leukaemia virus II genome determine target cell specificity. Nature (1984) 2.39
HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation. Science (1988) 2.37
Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature (1983) 2.36
Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol (1994) 2.36
Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol (1996) 2.33
Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest (1992) 2.28
Establishment of infection by spleen necrosis virus: inhibition in stationary cells and the role of secondary infection. J Virol (1982) 2.26
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22
A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A (1993) 2.15
Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity. J Biol Chem (1976) 2.14
Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod (1994) 2.12
Binding of host-cell factors to DNA sequences in the long terminal repeat of human T-cell leukemia virus type I: implications for viral gene expression. Proc Natl Acad Sci U S A (1988) 2.12
Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11
A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol (2001) 2.11
Nucleotide sequence of the 3' region of an infectious human T-cell leukemia virus type II genome. Proc Natl Acad Sci U S A (1984) 2.10
Rapid generation of sequence variation during primary HIV-1 infection. AIDS (1992) 2.08
Functional relation between HTLV-II x and adenovirus E1A proteins in transcriptional activation. Science (1985) 1.87
Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science (1998) 1.83
HIV-1 env sequence variation in brain tissue of patients with AIDS-related neurologic disease. J Acquir Immune Defic Syndr (1991) 1.72
Structure of a human DNA repair protein UBA domain that interacts with HIV-1 Vpr. Nat Struct Biol (1998) 1.69
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol (1995) 1.69
Substitution of 5' helper virus sequences into non-rel portion of reticuloendotheliosis virus strain T suppresses transformation of chicken spleen cells. Cell (1982) 1.69
Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol (1992) 1.66
HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J (1991) 1.66
Studies of the putative transforming protein of the type I human T-cell leukemia virus. Science (1985) 1.65
Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci U S A (1991) 1.62
An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol (1999) 1.61
Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol (2000) 1.61
Regulation of AIDS virus expression. Cell (1986) 1.57
Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells. J Virol (2000) 1.55
Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci U S A (1999) 1.52
Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. J Virol (1997) 1.52
Human immunodeficiency virus type 1 tropism for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J Virol (1992) 1.52
Characterization and expression of novel singly spliced RNA species of human immunodeficiency virus type 1. J Virol (1990) 1.48
Metal-dependent binding of a factor in vivo to the metal-responsive elements of the metallothionein 1 gene promoter. Mol Cell Biol (1987) 1.47
HTLV x-gene product: requirement for the env methionine initiation codon. Science (1985) 1.45
Expression of the 3' terminal region of human T-cell leukemia viruses. Science (1984) 1.44
A second isolate of HTLV-II associated with atypical hairy-cell leukemia. N Engl J Med (1986) 1.44
HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes. Science (1988) 1.41
Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med (1997) 1.41
Structure and expression of c-rel, the cellular homolog to the oncogene of reticuloendotheliosis virus strain T. J Virol (1983) 1.40
Characterization of a novel HTLV-infected cell line. Blood (1984) 1.40
Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J Virol (1997) 1.37
Regulation of human T cell leukemia virus expression. FASEB J (1990) 1.36
Detection and cloning of new HTLV-related endogenous sequences in man. Nucleic Acids Res (1989) 1.36
Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood (1994) 1.33
Human T-cell leukemia virus type II nucleotide sequences between env and the last exon of tax/rex are not required for viral replication or cellular transformation. J Virol (1995) 1.32
A new reporter system for detection of retroviral infection. Gene Ther (1995) 1.32
Induction of interleukin-1 and tumor necrosis factor alpha in brain cultures by human immunodeficiency virus type 1. J Virol (1992) 1.32
Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques. J Virol (2001) 1.30
Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol (1996) 1.27
Human immunodeficiency virus causes mononuclear phagocyte dysfunction. Proc Natl Acad Sci U S A (1990) 1.26
Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. Oncogene (1989) 1.22
Envelope gene of the human endogenous retrovirus HERV-W encodes a functional retrovirus envelope. J Virol (2001) 1.22
Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat Med (1997) 1.21
Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses. J Virol (1995) 1.21
A deletion in the proximal untranslated pX region of human T-cell leukemia virus type II decreases viral replication but not infectivity in vivo. Blood (1996) 1.20
Biochemical and structural analysis of the interaction between the UBA(2) domain of the DNA repair protein HHR23A and HIV-1 Vpr. Biochemistry (2000) 1.18
Lentiviral-mediated BMP-2 gene transfer enhances healing of segmental femoral defects in rats. Bone (2007) 1.16
Infection with HTLV-I and HTLV-II: evolving concepts. Semin Hematol (1988) 1.14
Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication. J Virol (2000) 1.12
Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet (1991) 1.12
Ribonucleotides in unintegrated linear spleen necrosis virus DNA. J Virol (1980) 1.12
Regions of human immunodeficiency virus type 1 nef required for function in vivo. J Virol (1998) 1.09
Lentiviral vectors--the promise of gene therapy within reach? Science (1999) 1.07
Modes of transformation by the human T-cell leukemia viruses. Mol Biol Med (1990) 1.06
Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood (1993) 1.06
Human T-cell leukemia virus infection of human hematopoietic progenitor cells: maintenance of virus infection during differentiation in vitro and in vivo. J Virol (1996) 1.05
CD26 antigen and HIV fusion? Science (1994) 1.05
A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users. Blood (1990) 1.05
The internal methionine codons of human T-cell leukemia virus type II rex gene are not required for p24rex production or virus replication and transformation. J Virol (1990) 1.04
Increased susceptibility of neonatal monocyte/macrophages to HIV-1 infection. AIDS Res Hum Retroviruses (1993) 1.04